Age group: From 12 years old
Gender: Male or Female
Duration: Up to 24 weeks approximately
Compensation: Up to $1,460
About this study:
The study is evaluating if an additional 5-day course of PAXLOVID may provide benefit for
adults and children at 12 years of age with rebound of COVID-19 symptoms and a SARS-CoV-2
infection within 14 days after completing an initial 5-day course of PAXLOVID.
Who can participate?
- Participants must be at least 12 years of age and weight at least 40 kg (88lb).
- Have completed an initial 5-day course of PAXLOVID (Nirmatrevir and ritonavir) and
experienced initial improvement in COVID-19 signs/symptoms followed by a worsening
(rebound) of COVID-19 signs/symptoms. - Are willing to take a COVID-19 test at a study site within 48 hours of first rebound
symptom. - Possibly have an increased risk of developing severe illness from COVID-19 (for
example but not limited to: High blood pressure, obesity, diabetes, heart disease)
Where is the study taking place?
The study is being conducted at our facility in Palmetto Medical Plaza.
NCT05567952
